Opportunity Information: Apply for PA 14 135
Apply for PA 14 135
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R34)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279 Drug Abuse and Addiction Research Programs.
- This funding opportunity was created on Mar 3, 2014 and posted on Mar 3, 2014.
- Applicants must submit their applications by May 7, 2017. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $225,000.00 in funding.
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification) Public and State controlled institutions of higher education County governments City or township governments Private institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses State governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts For profit organizations other than small businesses Native American tribal governments (Federally recognized) Special district governments Native American tribal organizations (other than Federally recognized tribal governments) Public housing authorities/Indian housing authorities.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R34) opportunity (Funding Opportunity Number PA-14-135) is a National Institutes of Health (NIH) discretionary grant that supports high-impact research focused on hepatitis C virus (HCV) prevention and treatment among people who use substances, including individuals who are infected with or at risk for HIV. The central aim is to reduce new HCV infections, improve identification of existing infections, and strengthen the effectiveness and reach of treatment approaches in populations where substance use increases risk and complicates access to care. The announcement is explicitly aligned with federal priorities laid out in the 2011 HHS Action Plan, "Combating the Silent Epidemic of Viral Hepatitis," which emphasizes coordinated strategies for prevention, screening, linkage to care, and treatment.
This FOA is designed to stimulate both clinical and basic research that can produce practical, scalable advances for these high-risk groups. In plain terms, NIH is seeking studies that can make prevention and treatment work better in real-world settings where substance use, co-occurring health conditions, and structural barriers (such as stigma, unstable housing, or limited healthcare access) often stand in the way. While the text provided does not list specific research topics in detail, it makes clear that priority is placed on approaches that reduce incidence (new infections) and that help health systems and community programs find, engage, and successfully treat people who are already infected. Because the population of interest includes those infected with or at risk for HIV, the scope naturally includes work at the intersection of HCV, HIV, and substance use, where integrated screening, prevention services, and treatment models are often needed.
The grant mechanism is an R34, which generally indicates support for the early stages of clinical research development, including pilot, feasibility, or preparatory studies that can lay the groundwork for larger-scale trials or broader implementation efforts. The award ceiling listed for this opportunity is $225,000, and the announcement notes that there is no cost sharing or matching requirement, meaning applicants are not required to provide non-federal matching funds as a condition of the award.
Eligibility is broad and intentionally inclusive to encourage participation from a wide range of organizations that can reach substance-using populations and conduct rigorous research. Eligible applicants include public and private institutions of higher education, nonprofit organizations (both with and without 501(c)(3) status), small businesses, for-profit organizations (other than small businesses), and multiple levels of government such as state, county, city/township, special district governments, and independent school districts. The opportunity also extends eligibility to Native American tribal governments (federally recognized) and tribal organizations (including those other than federally recognized), as well as public housing authorities and Indian housing authorities. In addition, the eligibility section explicitly calls out a wide range of institution types and community-based entities, including faith-based or community-based organizations, Historically Black Colleges and Universities (HBCUs), Hispanic-Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), and Alaska Native, Native Hawaiian, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs). Notably, non-U.S. entities are eligible to apply, including foreign organizations and foreign institutions, as well as foreign components of U.S. organizations as permitted under NIH policy, signaling NIH interest in globally relevant approaches and cross-setting learning where appropriate.
Key administrative details include the posting and creation date of March 3, 2014, with an original and current closing date of May 7, 2017, and an archive date of June 7, 2017, indicating that this particular announcement is no longer active for new submissions. The activity category is listed under Education and Health, and it is associated with CFDA number 93.279 (Drug Abuse and Addiction Research Programs), which reflects the strong connection to substance use research infrastructure and priorities. The official NIH listing and additional information were provided through the NIH grants guide page at http://grants.nih.gov/grants/guide/pa-files/PA-14-135.html, and technical assistance for accessing the announcement is routed through the NIH Office of Extramural Research webmaster contact.
FAQs: Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R34) - PA-14-135
What is the name of this grant opportunity?
The opportunity is titled "The Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R34)" under Funding Opportunity Number (FON) PA-14-135.
Which federal agency is offering this grant?
This is a National Institutes of Health (NIH) discretionary grant.
What is the main purpose of PA-14-135?
The main purpose is to support high-impact research focused on hepatitis C virus (HCV) prevention and treatment among people who use substances, including people who are infected with or at risk for HIV. The overarching goals include reducing new HCV infections, improving identification of existing infections, and strengthening the effectiveness and reach of treatment approaches in these populations.
What populations are the focus of this FOA?
The FOA focuses on people who use substances and who are at risk for or living with HCV, including individuals who are infected with or at risk for HIV.
What kinds of outcomes is NIH trying to improve through this FOA?
Based on the description provided, NIH is aiming to support research that helps (1) reduce incidence of HCV (new infections), (2) improve identification of existing HCV infections, and (3) increase the effectiveness and reach of treatment approaches in substance-using populations that face barriers to care.
Does the FOA emphasize real-world barriers to prevention and treatment?
Yes. The description emphasizes practical, scalable advances in real-world settings where substance use, co-occurring health conditions, and structural barriers (for example, stigma, unstable housing, or limited healthcare access) can interfere with prevention, screening, linkage to care, and treatment.
Is this FOA aligned with any federal strategy or action plan?
Yes. The announcement is explicitly aligned with the 2011 HHS Action Plan, "Combating the Silent Epidemic of Viral Hepatitis," which emphasizes coordinated strategies for prevention, screening, linkage to care, and treatment.
What type of grant mechanism is an R34 in this context?
The mechanism is R34, which generally supports early stages of clinical research development, including pilot, feasibility, or preparatory studies intended to lay the groundwork for larger trials or broader implementation efforts.
Does the FOA support clinical research, basic research, or both?
The FOA is designed to stimulate both clinical and basic research that can produce practical, scalable advances for the targeted high-risk groups.
Does the provided text list specific research topics?
No. The description does not provide a detailed list of specific research topics, but it clearly prioritizes approaches that reduce new infections and improve the ability of health systems and community programs to find, engage, and successfully treat people who are already infected.
How does HIV relate to the scope of this funding opportunity?
The population of interest includes people infected with or at risk for HIV, so the scope includes work at the intersection of HCV, HIV, and substance use. The description notes that integrated screening, prevention services, and treatment models are often needed in these settings.
What is the award ceiling for this opportunity?
The award ceiling listed is $225,000.
Is cost sharing or matching required?
No. The announcement notes there is no cost sharing or matching requirement, meaning applicants are not required to provide non-federal matching funds as a condition of the award.
Who is eligible to apply?
Eligibility is broad and includes: public and private institutions of higher education; nonprofit organizations (with or without 501(c)(3) status); small businesses; for-profit organizations (other than small businesses); and multiple levels of government (state, county, city/township, special district governments, and independent school districts).
Are tribal governments and tribal organizations eligible?
Yes. Eligible applicants include Native American tribal governments (federally recognized) and tribal organizations, including those other than federally recognized, as described in the eligibility section.
Are public housing authorities eligible?
Yes. Public housing authorities and Indian housing authorities are included in the eligibility list.
Are community-based and faith-based organizations eligible?
Yes. The eligibility section explicitly calls out faith-based or community-based organizations among the types of entities eligible to apply.
Are minority-serving institutions eligible to apply?
Yes. The eligibility list specifically mentions Historically Black Colleges and Universities (HBCUs), Hispanic-Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), and Alaska Native, Native Hawaiian, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs).
Can non-U.S. organizations apply?
Yes. The eligibility section indicates that non-U.S. entities are eligible, including foreign organizations and foreign institutions, as well as foreign components of U.S. organizations as permitted under NIH policy.
Is this funding opportunity currently open for new submissions?
No. The posting/creation date is March 3, 2014, the closing date is listed as May 7, 2017 (original and current), and the archive date is June 7, 2017. These dates indicate the announcement is no longer active for new submissions.
What is the CFDA number associated with this opportunity?
The opportunity is associated with CFDA 93.279, "Drug Abuse and Addiction Research Programs."
What activity category is listed for this grant?
The activity category is listed under Education and Health.
Where can applicants find the official NIH announcement page?
The official NIH grants guide page is listed as: http://grants.nih.gov/grants/guide/pa-files/PA-14-135.html
Where is technical help referenced for accessing the announcement?
Technical assistance for accessing the announcement is routed through the NIH Office of Extramural Research webmaster contact, as noted in the provided description.
Browse more opportunities from the same category: Education Health
Next opportunity: Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R21)
Previous opportunity: Expanding Coverage and Improving the Quality of Facility and Community Based Prevention of Mother to Child Transmission of HIV Programs in Two Regions of Cameroon under the Presidents Emergency Plan for AIDS Relief (PEPFAR)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 14 135
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 14 135) also looked into and applied for these:
| Funding Opportunity |
|---|
| Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R21) Apply for PA 14 136 Funding Number: PA 14 136 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R01) Apply for PA 14 137 Funding Number: PA 14 137 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Community Partnerships to Advance Research (CPAR) (R21) Apply for PA 14 141 Funding Number: PA 14 141 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Community Partnerships to Advance Research (CPAR) (R01) Apply for PA 14 142 Funding Number: PA 14 142 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Community Partnerships to Advance Research (CPAR) (R15) Apply for PA 14 140 Funding Number: PA 14 140 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Additional Research Training Positions for NIAAA , NIDA , or NCI Supported NRSA Institutional Training (T32) Grants (Admin Supp) Apply for PA 14 146 Funding Number: PA 14 146 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20) Apply for PAR 14 152 Funding Number: PAR 14 152 Agency: National Institutes of Health Category: Education Health Funding Amount: $275,000 |
| Core Infrastructure and Methodological Research for Cancer Epidemiology Cohorts (U01) Apply for PAR 14 160 Funding Number: PAR 14 160 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Effects of Cannabis Use and Cannabinoids on the Developing Brain (R03) Apply for PA 14 164 Funding Number: PA 14 164 Agency: National Institutes of Health Category: Education Health Funding Amount: $100,000 |
| Effects of Cannabis Use and Cannabinoids on the Developing Brain (R21) Apply for PA 14 162 Funding Number: PA 14 162 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Effects of Cannabis Use and Cannabinoids on the Developing Brain (R01) Apply for PA 14 163 Funding Number: PA 14 163 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Avenir Award Program for Genetics or Epigenetics of Substance Abuse (DP2) Apply for RFA DA 15 006 Funding Number: RFA DA 15 006 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Early Phase Clinical Trials in Imaging and Image Guided Interventions (R01) Apply for PAR 14 166 Funding Number: PAR 14 166 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Physical Sciences Oncology Centers (U54) Apply for PAR 14 169 Funding Number: PAR 14 169 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Avenir Award Program for Research on Substance Abuse and HIV/AIDS (DP2) Apply for RFA DA 15 007 Funding Number: RFA DA 15 007 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Healthy Habits Timing for Developing Sustainable Healthy Behaviors in Children and Adolescents (R21) Apply for PA 14 176 Funding Number: PA 14 176 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Healthy Habits Timing for Developing Sustainable Healthy Behaviors in Children and Adolescents (R01) Apply for PA 14 177 Funding Number: PA 14 177 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| mHealth Tools for Underserved Populations with Chronic Conditions to Promote Effective Patient Provider Communication, Adherence to Treatment and Self Management (R01) Apply for PA 14 180 Funding Number: PA 14 180 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| mHealth Tools for Underserved Populations with Chronic Conditions to Promote Effective Patient Provider Communication, Adherence to Treatment and Self Management (R21) Apply for PA 14 181 Funding Number: PA 14 181 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| National Cooperative Drug Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders, Drug or Alcohol Addiction (U01) Apply for PAR 14 184 Funding Number: PAR 14 184 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 14 135", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.